159,067 Shares in Biohaven Ltd. $BHVN Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new position in shares of Biohaven Ltd. (NYSE:BHVN) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 159,067 shares of the company’s stock, valued at approximately $2,367,000. The Manufacturers Life Insurance Company owned 0.11% of Biohaven at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. AQR Capital Management LLC grew its position in Biohaven by 49.4% in the 1st quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock valued at $2,761,000 after buying an additional 37,981 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Biohaven by 32.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock worth $1,747,000 after acquiring an additional 17,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Biohaven by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock valued at $14,174,000 after acquiring an additional 41,040 shares in the last quarter. Intech Investment Management LLC increased its stake in shares of Biohaven by 80.3% during the first quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock worth $1,481,000 after acquiring an additional 27,433 shares during the period. Finally, Quantbot Technologies LP raised its holdings in Biohaven by 1,097.8% during the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock worth $125,000 after purchasing an additional 8,102 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Trading Up 0.3%

Shares of Biohaven stock opened at $15.78 on Thursday. Biohaven Ltd. has a 12-month low of $7.48 and a 12-month high of $18.57. The company has a current ratio of 4.73, a quick ratio of 4.73 and a debt-to-equity ratio of 21.23. The stock has a market cap of $2.38 billion, a PE ratio of -3.40 and a beta of 1.28. The company has a 50-day moving average of $14.85 and a two-hundred day moving average of $11.96.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, research analysts anticipate that Biohaven Ltd. will post -3.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BHVN. Needham & Company LLC set a $11.00 price objective on Biohaven in a report on Monday, June 29th. Canaccord Genuity Group set a $21.00 price target on Biohaven in a research note on Friday, August 28th. TD Cowen reaffirmed a “buy” rating on shares of Biohaven in a report on Wednesday, August 26th. Royal Bank Of Canada increased their price objective on Biohaven from $22.00 to $23.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Biohaven in a report on Friday, August 28th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Biohaven currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.94.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.